Safety Remains Front Line Concern For Oral MS Drugs
Merck Serono’s cladribine Tablets and Novartis’ fingolimod could be relegated to second line or later treatments.
Merck Serono’s cladribine Tablets and Novartis’ fingolimod could be relegated to second line or later treatments.